{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:59:42Z","timestamp":1792789182554,"version":"4.5.0"},"reference-count":229,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Des Moines University","award":["IOER 112-3140"],"award-info":[{"award-number":["IOER 112-3140"]}],"id":[{"id":"https:\/\/ror.org\/058w59113","id-type":"ROR","asserted-by":"crossref"}]},{"award":["IOER 112-3140"],"award-info":[{"award-number":["IOER 112-3140"]}],"id":[{"id":"https:\/\/ror.org\/058w59113","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) resists checkpoint blockades outside uncommon molecularly selected populations. This narrative review relates clinical combination studies to four overlapping resistance mechanisms: deficient antigenicity, presentation and priming; restricted effector-cell access; suppressive myeloid and regulatory-cell programs; and T-cell dysfunction. The grouping is an organizing heuristic, not a validated treatment-selection algorithm. A source audit through 5 September 2026 reconciled a nonexhaustive inventory of 85 supplied study\/cohort entries and relevant additional reports; 84 inventory entries remain in the synthesis after the exclusion of 1 trial. Trial design, endpoint success, component attribution and pharmacodynamic evidence were assessed separately. PA.7 and CISPD3 did not improve their primary survival endpoints when checkpoint blockade was added to chemotherapy. Positive or apparently favorable findings require design-specific interpretation: NASCA changed several components, KG4\/2015 pooled randomized and nonrandomized controls, and early vaccine signals have not established a routine benefit. POLAR did not meet its co-primary activity criteria; preliminary SWOG S2001 results did not demonstrate benefits from adding pembrolizumab to olaparib. dMMR\/MSI-H remains an established tumor-agnostic selection biomarker, while exploratory PA.7 and tissue-state signatures require independent validation. Human immune changes, immunogenicity and target engagement should not be equated with clinical efficacy. Future trials should test defined component contributions, appropriate pharmacodynamic hypotheses and patient-reported outcomes, with sampling adapted to disease setting and feasibility.<\/jats:p>","DOI":"10.3390\/cancers18183019","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:59:03Z","timestamp":1789639143000},"page":"3019","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination Immunotherapy in Pancreatic Cancer: Current Clinical Evidence and Mechanistic Rationale for Overcoming a \u201cCold\u201d Tumor"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0144-0868","authenticated-orcid":false,"given":"Bode T.","family":"Eisenmenger","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology & Pathology, Des Moines University College of Osteopathic Medicine, West Des Moines, IA 50266, USA"},{"name":"Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6005-4133","authenticated-orcid":false,"given":"Abraham S.","family":"Rappaport","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam H.","family":"Connell","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor T.","family":"Petruc","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan J.","family":"Riordan","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2598-7895","authenticated-orcid":false,"given":"Mark R.","family":"Wakefield","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, USA"},{"name":"Ellis Fischel Cancer Center, University of Missouri School of Medicine, Columbia, MO 65212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiang","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology & Pathology, Des Moines University College of Osteopathic Medicine, West Des Moines, IA 50266, USA"},{"name":"Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, USA"},{"name":"Ellis Fischel Cancer Center, University of Missouri School of Medicine, Columbia, MO 65212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu. Rev. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and Activity of Anti\u2013PD-L1 Antibody in Patients with Advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or Without Tremelimumab for Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial","volume":"5","author":"Oh","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair\u2013Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kaplon, H. (2022). Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.835502"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41590-025-02134-6","article-title":"Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer","volume":"26","author":"Shakiba","year":"2025","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S2468-1253(23)00207-8","article-title":"The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy","volume":"8","author":"Hilmi","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Al-Khinji, A., Al-Korbi, N., Al-Kuwari, S., Al-Hor, A., and Malouche, D. (2025). Immune checkpoint inhibitors in pancreatic adenocarcinoma: A systematic review and meta analysis of clinical outcomes. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1569884"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Qi, X., Yang, H., Zhang, L., Yu, P., and Cheng, C. (2026). Advancing precision immunotherapy in advanced pancreatic cancer: A systematic review and meta-analysis of first-line ICI-based combinations. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1855859"},{"key":"ref_17","unstructured":"OCEBM Levels of Evidence Working Group (2026, August 29). The Oxford 2011 Levels of Evidence. Available online: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_20","first-page":"2127","article-title":"Methodological quality of case series studies: An introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (MINORS): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014A scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ijc.32186","article-title":"Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes","volume":"145","author":"Yau","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.7150\/thno.108925","article-title":"Single-nucleus RNA sequencing and spatial transcriptomics reveal an immunosuppressive tumor microenvironment related to metastatic dissemination during pancreatic cancer liver metastasis","volume":"15","author":"Liu","year":"2025","journal-title":"Theranostics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1038\/s41588-024-01914-4","article-title":"Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity","volume":"56","author":"Khaliq","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1101\/gad.348523.121","article-title":"The biological underpinnings of therapeutic resistance in pancreatic cancer","volume":"35","author":"Beatty","year":"2021","journal-title":"Genes Dev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"Sethna","year":"2022","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s44318-024-00319-7","article-title":"Hypoxia promotes tumor immune evasion by suppressing MHC-I expression and antigen presentation","volume":"44","author":"Estephan","year":"2025","journal-title":"EMBO J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","article-title":"Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer","volume":"37","author":"Hegde","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1053\/j.gastro.2013.07.025","article-title":"Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma","volume":"145","author":"Clear","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival","volume":"25","author":"Carstens","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1146\/annurev-cancerbio-061421-035400","article-title":"Cancer-Associated Fibroblasts: Lessons from Pancreatic Cancer","volume":"7","author":"Sherman","year":"2023","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","article-title":"Type I collagen deletion in \u03b1SMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Masugi, Y. (2022). The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities. Cancers, 14.","DOI":"10.3390\/cancers14133293"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gorchs, L., Oosthoek, M., Yucel-Lindberg, T., Moro, C.F., and Kaipe, H. (2022). Chemokine Receptor Expression on T Cells Is Modulated by CAFs and Chemokines Affect the Spatial Distribution of T Cells in Pancreatic Tumors. Cancers, 14.","DOI":"10.3390\/cancers14153826"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"15095","DOI":"10.1038\/ncomms15095","article-title":"Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer","volume":"8","author":"Carstens","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0360-3016(00)00803-8","article-title":"Pancreatic tumors show high levels of hypoxia","volume":"48","author":"Koong","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2020.07.041","article-title":"Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer","volume":"492","author":"Shah","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia","volume":"21","author":"Lee","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/gutjnl-2017-313738","article-title":"Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma","volume":"67","author":"Nywening","year":"2018","journal-title":"Gut"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","article-title":"Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity","volume":"63","author":"Stromnes","year":"2014","journal-title":"Gut"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1158\/2159-8290.CD-22-1046","article-title":"Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer","volume":"13","author":"Bianchi","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/MPA.0000000000001621","article-title":"T-Cell Immunity in Pancreatic Cancer","volume":"49","author":"Ajina","year":"2020","journal-title":"Pancreas"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.21873\/anticanres.15824","article-title":"Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis","volume":"42","author":"Nakayama","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Seifert, L., Plesca, I., M\u00fcller, L., Sommer, U., Heiduk, M., von Renesse, J., Digomann, D., Gl\u00fcck, J., Klimova, A., and Weitz, J. (2021). LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer. Cancers, 13.","DOI":"10.3390\/cancers13061297"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00262-026-04343-w","article-title":"Protein-level profiling of TIGIT axis components in human PDAC reveals immune\u2013suppressive expression patterns","volume":"75","author":"Quatannens","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s43018-020-00121-4","article-title":"Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer","volume":"1","author":"Steele","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41588-022-01134-8","article-title":"Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment","volume":"54","author":"Hwang","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","article-title":"Spatially confined sub-tumor microenvironments in pancreatic cancer","volume":"184","author":"Devisme","year":"2021","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/2326-6066.CIR-20-0785","article-title":"Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming","volume":"9","author":"Diamond","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1073\/pnas.1918971117","article-title":"Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity","volume":"117","author":"Morrison","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","first-page":"62","article-title":"Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer","volume":"4","author":"Gulhati","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/2326-6066.CIR-25-0575","article-title":"Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma","volume":"13","author":"Stone","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/gutjnl-2022-327927","article-title":"FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer","volume":"73","author":"Canel","year":"2024","journal-title":"Gut"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e003254","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects","volume":"9","author":"Laquente","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.2020.38.4_suppl.638","article-title":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa with Nab-Paclitaxel Plus Gemcitabine for Patients with Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","volume":"38","author":"Tempero","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41591-025-04043-5","article-title":"Autologous multiantigen-targeted T cell therapy for pancreatic cancer: A phase 1\/2 trial","volume":"32","author":"Musher","year":"2026","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1016\/j.ymthe.2026.03.012","article-title":"T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1\/2 clinical trial","volume":"34","author":"Xu","year":"2026","journal-title":"Mol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Seo, H., Go, D., Jung, S.Y., Han, S., Nguyen, V.Q., Kwak, M., and Um, W. (2025). Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma. Biomolecules, 15.","DOI":"10.3390\/biom15101477"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A Phase II Study of Allogeneic GM-CSF\u2013Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study","volume":"22","author":"Varadhachary","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Maurer","year":"2022","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): A single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Borbath","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","article-title":"A Phase 3 Randomized Clinical Trial of Chemotherapy with or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41467-026-68324-4","article-title":"Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: A phase I trial","volume":"17","author":"Huff","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41416-023-02474-w","article-title":"Efficacy of GV1001 with gemcitabine\/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4\/2015): An open-label, randomised, Phase 3 trial","volume":"130","author":"Jo","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/cas.12674","article-title":"Randomized phase II\/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study","volume":"106","author":"Yamaue","year":"2015","journal-title":"Cancer Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/mt.2016.66","article-title":"Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma","volume":"24","author":"Noonan","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): Results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/bjc.2016.271","article-title":"Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer","volume":"115","author":"Dalgleish","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","article-title":"STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models","volume":"7","author":"Jing","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e004784","DOI":"10.1136\/jitc-2022-004784","article-title":"Toll-like receptor 7\/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer","volume":"10","author":"Ye","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized Phase II Study of Nivolumab with or Without Ipilimumab Combined with Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)","volume":"40","author":"Chen","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-19-3624","article-title":"Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","volume":"26","author":"Xie","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","article-title":"Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study","volume":"28","author":"Lim","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"553\u2013e472","DOI":"10.1093\/oncolo\/oyad022","article-title":"Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib\/II Umbrella Randomized Study Platform","volume":"28","author":"Ko","year":"2023","journal-title":"Oncologist"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Chiorean, E.G., Damle, S.R., Zhen, D.B., Whittle, M., George, B., Hochster, H., Coveler, A.L., Hendifar, A., Dragovich, T., and Safyan, R.A. (2026). Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001. Cancers, 18.","DOI":"10.3390\/cancers18030507"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: The COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","article-title":"Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT\/KEYNOTE-202 Trial","volume":"27","author":"Bockorny","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"oyag023","DOI":"10.1093\/oncolo\/oyag023","article-title":"Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: Phase I\/IIb MORPHEUS-PDAC umbrella study","volume":"31","author":"Manji","year":"2026","journal-title":"Oncologist"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","article-title":"Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: A phase 2 clinical trial","volume":"15","author":"Baretti","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e002068","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e011284","DOI":"10.1136\/jitc-2024-011284","article-title":"Phase 1b\/2 study of BMS-813160, a CCR2\/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer","volume":"14","author":"Le","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","article-title":"Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer","volume":"119","author":"Melisi","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41591-026-04283-z","article-title":"Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: A randomized phase 1 trial","volume":"32","author":"Wainberg","year":"2026","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1158\/1078-0432.CCR-24-0499","article-title":"A Phase Ib\/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","volume":"30","author":"Coveler","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-020-00260-1","article-title":"Irreversible electroporation plus allogenic V\u03b39V\u03b42 T cells enhances antitumor effect for locally advanced pancreatic cancer patients","volume":"5","author":"Lin","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s12032-013-0747-9","article-title":"S-1 plus CIK as second-line treatment for advanced pancreatic cancer","volume":"30","author":"Wang","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.01.031","article-title":"Trials and tribulations of pancreatic cancer immunotherapy","volume":"504","author":"Principe","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41467-026-70120-z","article-title":"DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with\/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma","volume":"17","author":"Renouf","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1245\/s10434-023-13383-w","article-title":"Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial","volume":"30","author":"Fu","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41392-025-02441-2","article-title":"First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: A phase Ib\/II randomized study","volume":"10","author":"Jia","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10637-017-0525-1","article-title":"Phase Ib\/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma","volume":"36","author":"Weiss","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s44276-023-00028-4","article-title":"A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer","volume":"2","author":"Morizane","year":"2024","journal-title":"BJC Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1038\/s41467-026-68976-2","article-title":"Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: A pilot phase 1 trial","volume":"17","author":"Wainberg","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","article-title":"Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer","volume":"26","author":"Wainberg","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/annonc\/mdu205","article-title":"A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer","volume":"25","author":"Aglietta","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1634\/theoncologist.2019-0473","article-title":"Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study","volume":"25","author":"Kamath","year":"2020","journal-title":"Oncologist"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"102407","DOI":"10.1016\/j.xcrm.2025.102407","article-title":"CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1","volume":"6","author":"Geboes","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Pelletier, M., Yang, J., Joshi, M., Grauel, A., Abecunas, C., Altzerinakou, M.A., Zhou, Z., Zhu, X., Clark, K., and Li, L. (2026). Biomarker Analysis from Patients with Metastatic PDAC Treated with TGF\u03b2 Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study. Clin. Cancer Res., OF1\u2013OF15.","DOI":"10.1158\/1078-0432.33775723"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/1078-0432.CCR-21-2495","article-title":"Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy","volume":"28","author":"Mills","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Kerschbaum-Gruber, S., Kleinw\u00e4chter, A., Popova, K., Kneringer, A., Appel, L.M., Stasny, K., R\u00f6hrer, A., Dias, A.B., Benedum, J., and Walch, L. (2024). Cytosolic nucleic acid sensors and interferon beta-1 activation drive radiation-induced anti-tumour immune effects in human pancreatic cancer cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1286942"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e130362","DOI":"10.1172\/jci.insight.130362","article-title":"Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy","volume":"5","author":"Farren","year":"2020","journal-title":"JCI Insight"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e007586","DOI":"10.1136\/jitc-2023-007586","article-title":"Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma","volume":"11","author":"Katz","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2022.11.035","article-title":"Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)","volume":"180","author":"Chen","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40487-024-00309-z","article-title":"Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1\/2 Clinical CA209-9KH Trial","volume":"12","author":"John","year":"2024","journal-title":"Oncol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/1078-0432.CCR-25-2461","article-title":"Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel\/Gemcitabine as Conversion Therapy for BRPC\/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring","volume":"32","author":"Ni","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2543614","DOI":"10.1080\/2162402X.2025.2543614","article-title":"A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages","volume":"14","author":"Bever","year":"2025","journal-title":"Oncoimmunology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1158\/1078-0432.CCR-24-1821","article-title":"Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer","volume":"31","author":"Grierson","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/2326-6066.CIR-23-1073","article-title":"Blockade of IL1\u03b2 and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor","volume":"12","author":"Oberstein","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e000587","DOI":"10.1136\/jitc-2020-000587","article-title":"Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer","volume":"8","author":"Overman","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1158\/2767-9764.CRC-26-0018","article-title":"Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study","volume":"6","author":"Rha","year":"2026","journal-title":"Cancer Res. Commun."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e007883","DOI":"10.1136\/jitc-2023-007883","article-title":"Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)","volume":"12","author":"Callahan","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e012864","DOI":"10.1136\/jitc-2025-012864","article-title":"Clinical and translational results from a phase 1 trial of gemcitabine\/nab-paclitaxel with nivolumab\/ipilimumab or hydroxychloroquine\/ipilimumab in untreated metastatic pancreatic adenocarcinoma","volume":"14","author":"Cabanski","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and Survival with GVAX Pancreas Prime and Listeria Monocytogenes\u2013Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer","volume":"33","author":"Le","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","article-title":"Evaluation of Cyclophosphamide\/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer","volume":"26","author":"Tsujikawa","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","article-title":"Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)","volume":"25","author":"Le","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of Ipilimumab in Combination with Allogeneic Pancreatic Tumor Cells Transfected with a GM-CSF Gene in Previously Treated Pancreatic Cancer","volume":"36","author":"Le","year":"2013","journal-title":"J. Immunother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-24-3403","article-title":"A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma","volume":"31","author":"Agarwal","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1158\/2326-6066.CIR-25-0545","article-title":"A Randomized Phase II Study: CRS207\/GVAX plus Anti\u2013PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC","volume":"14","author":"Bever","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11605-012-2064-6","article-title":"Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: A Phase 2 Study","volume":"17","author":"Hardacre","year":"2013","journal-title":"J. Gastrointest. Surg."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2326-6066.CIR-17-0386","article-title":"Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study","volume":"6","author":"Nishida","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/cas.14106","article-title":"Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma","volume":"110","author":"Shima","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/CJI.0000000000000020","article-title":"Wilms Tumor Gene (WT1) Peptide\u2013based Cancer Vaccine Combined with Gemcitabine for Patients with Advanced Pancreatic Cancer","volume":"37","author":"Nishida","year":"2014","journal-title":"J. Immunother."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41392-025-02488-1","article-title":"Dynamic transcriptional immune landscape in response to NK-cell therapy combined with gemcitabine plus S-1 in advanced pancreatic cancer: A phase 1b\/2 trial","volume":"10","author":"Tan","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jcyt.2017.01.002","article-title":"Adjuvant combination therapy with gemcitabine and autologous \u03b3\u03b4 T-cell transfer in patients with curatively resected pancreatic cancer","volume":"19","author":"Aoki","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: A randomised, phase 1b\/2 trial","volume":"23","author":"Reiss","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/s41591-026-04299-5","article-title":"Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: The phase 2 POLAR trial","volume":"32","author":"Park","year":"2026","journal-title":"Nat. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2026.44.16_suppl.4012","article-title":"Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1\/2) mutations: SWOG S2001","volume":"44","author":"Chung","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"113950","DOI":"10.1016\/j.ejca.2024.113950","article-title":"A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for \u22653rd-line treatment of patients with advanced pancreatic adenocarcinoma","volume":"201","author":"Enzler","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_156","first-page":"272","article-title":"A Phase II, Open-Label, Randomized Trial of Durvalumab with Olaparib or Cediranib in Patients with Mismatch Repair\u2014Proficient Colorectal or Pancreatic Cancer","volume":"23","author":"Han","year":"2024","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2020.38.15_suppl.3059","article-title":"Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts","volume":"38","author":"Matrana","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","article-title":"Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy","volume":"615","author":"Sennino","year":"2023","journal-title":"Nature"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Klar","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Martin, S.D., Brown, S.D., Wick, D.A., Nielsen, J.S., Kroeger, D.R., Twumasi-Boateng, K., Holt, R.A., and Nelson, B.H. (2016). Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155189"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1016\/j.cell.2021.08.020","article-title":"Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors","volume":"184","author":"Burger","year":"2021","journal-title":"Cell"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nm.3105","article-title":"Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion","volume":"19","author":"Hailemichael","year":"2013","journal-title":"Nat. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","article-title":"LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity","volume":"611","author":"Krishnamurty","year":"2022","journal-title":"Nature"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-19-0454","article-title":"Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis","volume":"79","author":"Mizutani","year":"2019","journal-title":"Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1158\/0008-5472.CAN-22-1190","article-title":"Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers","volume":"82","author":"Mi","year":"2022","journal-title":"Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1158\/0008-5472.CAN-21-3603","article-title":"Macrophage-Targeting by CSF1\/1R Blockade in Pancreatic Cancers","volume":"81","author":"Ho","year":"2021","journal-title":"Cancer Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 Agonist Antibodies in Cancer Immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: Histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2023.04.012","article-title":"Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort","volume":"188","author":"Sayah","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e004485","DOI":"10.1136\/jitc-2021-004485","article-title":"Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer","volume":"10","author":"Chakrabarti","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_174","unstructured":"U.S. Food and Drug Administration (2026, September 01). KEYTRUDA (Pembrolizumab) Injection, for Intravenous Use: Highlights of Prescribing Information (BLA 125514, Supplement 190), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/125514s190lbl.pdf."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41698-024-00679-7","article-title":"Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab","volume":"8","author":"Lin","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_176","unstructured":"U.S. Food and Drug Administration (2026, September 05). VENTANA MMR RxDx Panel: Premarket Approval P210001, Supplement S001, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P210001S001."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e2200706","DOI":"10.1200\/PO.22.00706","article-title":"Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience","volume":"7","author":"Coston","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00432-025-06334-3","article-title":"Response to PD-1 inhibition in MMRd\/MSS pancreatic ductal adenocarcinoma: The relevance of parallel testing","volume":"151","author":"Pahl","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden\u2013High Solid Tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Lawlor, R.T., Mattiolo, P., Mafficini, A., Hong, S.M., Piredda, M.L., Taormina, S.V., Malleo, G., Marchegiani, G., Pea, A., and Salvia, R. (2021). Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers, 13.","DOI":"10.3390\/cancers13133119"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2022.03.033","article-title":"High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity","volume":"169","author":"Karamitopoulou","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e2300092","DOI":"10.1200\/PO.23.00092","article-title":"Tumor Mutational Burden in Real-World Patients with Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness","volume":"7","author":"Quintanilha","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40164-025-00673-0","article-title":"Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancer","volume":"14","author":"Lei","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Golesworthy, B., Wang, Y., Tanti, A., Pacis, A., Romero, J.M., Cuggia, A., Domecq, C., Bourdel, G., Denroche, R.E., and Jang, G.H. (2022). Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.860767"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Gao, Z., Azar, J., Zhu, H., Williams-Perez, S., Kang, S.W., Marginean, C., Rubinstein, M.P., Makawita, S., Lee, H.S., and Camp, E.R. (2024). Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1324093"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e86125","DOI":"10.7554\/eLife.86125","article-title":"Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma","volume":"12","author":"Croft","year":"2023","journal-title":"Elife"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"103489","DOI":"10.1016\/j.esmoop.2024.103489","article-title":"Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma","volume":"9","author":"Christensen","year":"2024","journal-title":"ESMO Open"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1900635","DOI":"10.1080\/2162402X.2021.1900635","article-title":"Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer","volume":"10","author":"Gunderson","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Rogers, S., Charles, A., and Thomas, R.M. (2023). The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer. Cancers, 15.","DOI":"10.3390\/cancers15245708"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1111\/cas.15901","article-title":"Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1-CXCR2 axis","volume":"114","author":"Hayashi","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Wu, M., Li, G., Li, Y., Chen, K., Xu, M., Li, D., Xu, C., Shen, M., Li, W., and Cao, J. (2025). Multi-omics analyses inform mechanisms of immunotherapy response in pancreatic cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1673098"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Dopico, P.J., Le, M.C.N., Burgess, B., Yang, Z., Zhao, Y., Wang, Y., George, T.J., and Fan, Z.H. (2022). Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Biosensors, 12.","DOI":"10.3390\/bios12040206"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/a-2524-2596","article-title":"Endoscopic ultrasound-guided tissue sampling: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review","volume":"57","author":"Facciorusso","year":"2025","journal-title":"Endoscopy"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/a-1915-5263","article-title":"Endoscopic ultrasound-guided fine-needle biopsy with or without macroscopic on-site evaluation: A randomized controlled noninferiority trial","volume":"55","author":"Mangiavillano","year":"2023","journal-title":"Endoscopy"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","article-title":"Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative","volume":"24","author":"Pishvaian","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/jgh.14540","article-title":"Comparison of endoscopic ultrasound tissue acquisition methods for genomic analysis of pancreatic cancer","volume":"34","author":"Elhanafi","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Mohamed, W.T., Jahagirdar, V., Jaber, F., Ahmed, M.K., Fatima, I., Bierman, T., Fu, Z., Jones, P.G., Hassan, A.F., and Faber, E. (2024). Endoscopic Ultrasound-Guided Fine-Needle Biopsy Versus Aspiration for Tissue Sampling Adequacy for Molecular Testing in Pancreatic Ductal Adenocarcinoma. Cancers, 16.","DOI":"10.3390\/cancers16040761"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Botrus, G., Uson Junior, P.L.S., Raman, P., Kaufman, A.E., Kosiorek, H., Yin, J., Fu, Y., Majeed, U., Sonbol, M.B., and Ahn, D.H. (2022). Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients with Worse Overall Survival. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.794009"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"10202","DOI":"10.1073\/pnas.1704961114","article-title":"Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers","volume":"114","author":"Cohen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0959-8049(99)00047-7","article-title":"Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer","volume":"35","author":"Fitzsimmons","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1245\/s10434-021-09816-z","article-title":"Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma","volume":"28","author":"Reni","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.hpb.2019.09.002","article-title":"Patient-reported outcome measures (PROMs) in pancreatic cancer: A systematic review","volume":"22","author":"Maharaj","year":"2020","journal-title":"HPB"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s43441-024-00698-3","article-title":"Latest Developments in \u201cAdaptive Enrichment\u201d Clinical Trial Designs in Oncology","volume":"58","author":"Tu","year":"2024","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Liang, K.L., and Azad, N.S. (2025). Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting. Cancers, 17.","DOI":"10.3390\/cancers17071246"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e015122","DOI":"10.1136\/jitc-2026-015122","article-title":"Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: Results of the MITRIC trial","volume":"14","author":"Ullern","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ijrobp.2024.10.039","article-title":"Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor\u2013Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma","volume":"121","author":"Hill","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-25-4396","article-title":"Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I\/IIb Clinical Trial","volume":"32","author":"Hahn","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/ijc.30510","article-title":"Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients","volume":"140","author":"Miyazawa","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"100972","DOI":"10.1016\/j.xcrm.2023.100972","article-title":"PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC\/LAPC: A biomolecular exploratory, phase II trial","volume":"4","author":"Du","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/cas.13113","article-title":"Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study","volume":"108","author":"Suzuki","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41392-024-01857-6","article-title":"First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel\/gemcitabine (PAAG) in metastatic pancreatic cancer: A prospective, multicentre, biomolecular exploratory, phase II trial","volume":"9","author":"Sha","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41392-024-02031-8","article-title":"Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: A phase Ib\/II trial","volume":"9","author":"Cheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41392-025-02530-2","article-title":"A phase 1b\/2 study of first-line anti-PD-L1\/TGF-\u03b2RII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma","volume":"10","author":"Xue","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00262-024-03744-z","article-title":"Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: A single-arm, phase II clinical trial","volume":"73","author":"Wang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"oyag091","DOI":"10.1093\/oncolo\/oyag091","article-title":"Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma","volume":"31","author":"Safyan","year":"2026","journal-title":"Oncologist"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/1078-0432.CCR-21-3009","article-title":"ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b\/2 Study","volume":"28","author":"Johnson","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1038\/s41467-026-69294-3","article-title":"The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: A single-arm, phase II study","volume":"17","author":"Lee","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"eadk1827","DOI":"10.1126\/sciadv.adk1827","article-title":"Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells","volume":"10","author":"Wang","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41416-020-0752-7","article-title":"TG01\/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): A single-arm, phase 1\/2 trial","volume":"122","author":"Palmer","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1080\/21645515.2021.2003645","article-title":"Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and\/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy","volume":"17","author":"Ota","year":"2021","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/3019\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:20:29Z","timestamp":1789640429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/3019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":229,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18183019"],"URL":"https:\/\/doi.org\/10.3390\/cancers18183019","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}